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Abstract 
Oncogenes can induce p53 through a signaling pathway involving p19/Arf.  It was recently 
proposed that oncogenes can also induce DNA damage and this can induce p53 through the Atm 
DNA damage pathway.  To assess the relative roles of Atm, Arf, and p53 in suppression of Ras- 
driven tumors we examined susceptibility to skin carcinogenesis in DMBA/TPA treated Atm and 
p53 deficient mice and compared these results to previous studies on Arf deficient mice.  Mice with 
epidermal specific deletion of p53 showed increased papilloma number and progression to 
malignant invasive carcinomas compared to wild type littermates.  In contrast, Atm deficient mice 
showed no increase in papilloma number, growth, or malignant progression.  γ-H2AX and p53 
levels were increased in both Atm+/+ and Atm-/- papillomas, while Arf-/- papillomas showed much 
lower p53 expression.  Thus although there is evidence of DNA damage, signaling through Arf 
appears to regulate p53 in these Ras-driven tumors.  In spontaneous and radiation induced 
lymphoma models, tumor latency was accelerated in Atm-/-p53-/- compound mutant mice 
compared to the single mutant Atm-/- or p53-/- mice, indicating cooperation between loss of Atm 
and loss of p53.  Although p53 mediated apoptosis was impaired in irradiated Atm-/- lymphocytes, 
p53 loss was still selected for during lymphomagenesis in Atm-/- mice.  In conclusion, in these 
models of oncogene or DNA damage induced tumors, p53 retains tumor suppressor activity in the 
absence of Atm. 
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Introduction.   
Carcinogenesis is an evolutionary process driven by mutation and selection 25.  In order to 
intervene in cancer development, it is important to understand the selective pressures which drive 
tumor evolution.  The observation that p53 mutations are found at high frequency in most types of 
human cancers 18 indicates selection for cells which have disabled p53 is a nearly universal feature 
of cancer.  p53 can be activated by numerous stressors including DNA damage, oncogene 
activation, abnormal cell adhesion, altered ribonucleotide pools, hypoxia, telomere erosion, and 
nutrient deprivation 15;48.  Activated p53 in turn, can suppress tumor development through the 
induction of cell cycle arrest, senescence, or apoptosis 48.  Of the many signals that have been 
reported to phosphorylate and activate p53, it is unclear which of these is physiologically relevant 
for tumor suppression in vivo.  This is further complicated by variations between tissues and tumor 
etiology.  DNA damage and activated oncogenes play direct causal roles in cancer induction and 
p53 activation and so both are reasonable candidates for generating selective pressure against 
p53 during tumor progression.   
DNA damage is the best studied activator of p53.  DNA double strand breaks (dsbs), which can be 
induced by ionizing radiation (IR) or other genotoxic agents, trigger a signaling cascade leading to 
p53-dependent cell cycle arrest or apoptosis.  The protein kinase ATM, which is mutated in the 
inherited syndrome ataxia telangiectasia (AT), is a primary signal transducer for the cellular 
response to dsbs 43.  DNA dsbs activate ATM, which can directly phosphorylate p53 on Ser15 1;8.  
ATM also phosphorylates Chk2, which in turn phosphorylates p53 on Ser 20 9;42.  ATM impairs the 
activity of negative regulators of p53, including the ubiquitin ligases cop1 and mdm2 14;34.  
Collectively, these alterations lead to the rapid accumulation of p53 and activation of its 
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transcriptional functions, which, in turn, can trigger cellular responses such as cell cycle arrest or 
apoptosis.  
AT patients carry homozygous mutations in ATM and have an increased risk of developing 
lymphoreticular malignancies 11.  Atm knockout mice are highly susceptible to lymphoid 
malignancies, but have not shown a marked predisposition to tumors in other tissues 3;50.  The 
basis for this tissue specificity is not known.  Westphal et al. reported that loss of Atm and p53 
cooperate to suppress spontaneous development of lymphomas 49.  Liao et al. demonstrated that 
p53 dependent tumor suppression in a mouse brain tumor model driven by truncated SV40 T 
antigen is unaffected by Atm deficiency 31.  In these mouse models, Atm does not appear to be an 
essential regulator of the tumor suppressor function of p53.  Several recent studies showed that 
Atm deficiency accelerates Myc and mutant Apc driven tumors suggesting Atm plays role in these 
tumor models 29;32;38.   
Atm-dependent signaling in vivo is markedly tissue specific.  Atm-/- mice have impaired p53-
dependent apoptosis in irradiated lymphoid tissue and the developing central nervous system as 
compared to wild type mice 2;20;51.  However, after a slight delay, p53 induction and apoptotic 
responses are largely intact in epithelial cells within hair follicles and intestinal crypts from 
irradiated Atm null mice 17.  This indicates Atm plays a critical role in DNA damage triggered 
apoptosis in lymphoid cells but there are alternative pathways in epithelial tissues which can 
compensate in the absence of Atm.  The presence of redundant DNA damaging signaling 
pathways in some tissues such as epithelium may explain the narrow tumor spectrum observed in 
Atm deficient mice.   
A long standing question concerning the model where DNA damage provides selective pressure 
against p53 is the source of DNA damage in tumors.  Several recent studies showed that 
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premalignant human lesions have constitutively active DNA damage signaling, as determined by 
staining for γ-H2AX, activated ATM, CHK-2, and p53 4;16.  It was further shown that oncogenes 
such as Ras can induce DNA damage and Atm signaling which can then trigger p53-mediated 
senescence and tumor suppression 5;12.  Here we test the role of Atm during tumor evolution by 
comparing the effects of Atm and p53 loss in epithelial and lymphoid tumor models.   
 
Results 
We first tested the role of Atm in suppressing Ras-driven tumors by examining the susceptibility of 
Atm deficient mice to DMBA/TPA induced skin tumors.  This protocol involves the topical 
application of the carcinogen DMBA to the dorsal skin, followed by twice weekly applications of the 
tumor promoter TPA.  This induces benign squamous cell papillomas, a small percentage of which 
can progress to malignant squamous cell carcinomas after a long latency.  Mutation of Hras is the 
initiating event in this tumor model and is detected in ~90% of both papillomas and carcinomas 39.  
Mutational inactivation of p53 occurs late and is strongly associated with papilloma to carcinoma 
conversion 7.  A causal role for p53 in malignant progression was established using germline p53 
knockout mice, which showed a markedly accelerated rate of carcinoma formation 26.  That 
mutations in Hras and p53 occur reproducibly at defined stages in this model facilitates the 
evaluation of the interaction between Atm with these cancer genes in the context of developing 
autochthonous tumors.   
100% of DMBA/TPA treated Atm+/+, Atm+/-, and Atm-/- mice developed papillomas, which first 
appeared between 7-9 weeks post-DMBA treatment.  The average number of papillomas per 
mouse was similar for all genotypes through 25 weeks of observation (Figure 1B).  The growth rate 
of papillomas, as measured by tumor size was also similar for all genotypes through 15 weeks, but 
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slightly reduced in Atm null mice after 15 weeks (Figure 1A).  Carcinomas first appeared in Atm+/+, 
Atm+/-, and Atm-/- mice at 15, 22, and 25 weeks, respectively.  The latency to carcinoma formation 
is shown by Kaplan-Meier plots in Figure 1C.  The median age for carcinoma development was 29, 
32, and 27 weeks for Atm +/+, Atm +/-, and Atm-/- mice, respectively and these values were not 
significantly different.  However during the course of this study, many Atm null mice died of 
lymphomas (Figure 1D), and some of these died before any reasonable chance of progression to 
carcinomas.  Therefore we also analyzed the conversion frequency of papillomas to carcinomas for 
mice that lived at least 20 weeks post DMBA.  Table 1 shows the percentage of papillomas that 
progressed to carcinomas was 5.6%, 8.3% and 5.0% in Atm+/+, Atm+/- and Atm-/- mice 
respectively.  These frequencies were not significantly different using the two-sided Fisher’s exact 
test.  Taken together, these results show that homozygous or hemizygous Atm deficiency did not 
significantly enhance Hras-driven tumor number, growth rate, or malignant progression.   
In order to compare these results to the effects of p53 loss on skin tumor progression, we repeated 
the DMBA/TPA protocol on p53 deficient mice.  We previously reported accelerated malignant 
progression in germline p53 deficient mice 26 and here we show similar effects with conditional p53 
deficient mice (see Materials and Methods) 23.  The average number of papillomas was similar 
between Trp53F2-10/F2-10; K14-Cre (skin-specific p53 deficient) mice compared to Trp53F2-10/F2-10 
(p53 wild type) mice through 15 weeks.  However, new tumors continued to appear in p53 deficient 
mice after this time, while plateauing in the wild types (Figure 1E).  Carcinomas first appeared in 
Trp53F2-10/F2-10; K14-Cre mice at 15 weeks and by 30 weeks, 75% of conditional p53 deficient mice 
averaged 2 carcinomas per mouse (Figure 1F).  In contrast, wild type littermates did not develop 
any carcinomas until after 30 weeks.  This difference was highly significant (p=0.001). Thus, skin-
specific p53 deletion markedly accelerates malignant skin tumor progression, a result similar to 
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that seen in p53 germline nullizygous mice 24;26.  This establishes that the effect of p53 on 
inhibiting malignant progression is tumor cell autonomous.  Both the Atm and p53 skin tumor 
studies were done using littermate wild type controls.  This is important as the wild type mice from 
the two studies differed in carcinoma susceptibility, likely due to different genetic backgrounds (see 
Materials and Methods).  Comparison between these two skin tumor studies reveals that p53 has a 
more significant impact on suppressing Ras-driven tumor progression than does Atm.  
We next addressed if DNA damage signaling was prominent in papillomas and if this led to Atm-
dependent expression of p53.  H2AX is rapidly phosphorylated in response to DNA double strand 
breaks 40 and phospho-H2AX (γ-H2AX) is widely used as a marker of DNA damage.  However γ-
H2AX also increases in M phase cells without DNA damage 21;35 and can be readily detected in 
epithelial cells during the hair cycle phase in untreated mouse skin 28.  Staining for γ-H2AX was 
seen in the occasional cell within the hair follicle of normal skin and in basal and suprabasal cells 
of the papillomas (Figure 2A).  Although Atm can phosphorylate H2AX after IR44 we observed 
similar levels of γ-H2AX staining in papillomas from Atm+/+ and Atm-/- mice indicating there are 
kinases that can substitute for Atm to phosphorylate H2AX in vivo.  Despite γ-H2AX staining, 
phospho-Chk2, a marker of DNA damage signaling, was low or undetectable in both Atm+/+ and 
Atm-/- papillomas (Figure 2B).  As a positive control, staining for p-Chk2 was seen in irradiated 
intestinal crypts (data not shown).  p53 was undetectable in normal skin but prominent in 
papillomas and primarily localized to keratinocytes within the basal layer (Figure 2).  Equivalent 
levels and cellular distribution patterns of p53 staining were seen in papillomas from Atm+/+ and 
Atm-/- mice.  Expression of the p53 regulated gene p21 (Cdkn1a), and the Cdk inhibitor p16 
(Ink4a), were also seen in both Atm+/+ and Atm-/- papillomas.  As another measure of p53 
functionality, we quantified proliferation and apoptosis.  The mitotic index was similar in papillomas 
 8
from Atm+/+ and Atm-/- mice, while the apoptotic index, as measured by both active caspase 3 
and apoptotic figures, was slightly elevated in Atm-/- papillomas (Figure 2B).  Thus Atm deficiency 
did not measurably affect levels of H2AX, p53, p21, or cell proliferation in benign tumors.   
It is useful to compare these results to those seen in p19/Arf null mice.  Arf is a tumor suppressor 
that induces p53 in response to oncogenic activation 36;41.  We previously showed accelerated 
papilloma to carcinoma progression in Arf deficient mice using an identical DMBA/TPA protocol 24.   
In comparison to papillomas from wild type and Atm null mice, Arf null papillomas showed reduced 
p53 expression and higher H2AX staining and increased mitotic activity (Figure 2).  This confirms 
our previous findings that Arf plays a critical role in the induction of p53 during benign tumor 
growth.  Reduced p53 could explain the increased proliferation in these tumors and this may 
contribute to increased levels of H2AX.  However the DNA damage p53 pathway is still functional 
in these tumors as irradiated tumor bearing Arf-/- mice showed robust p53 induction in papillomas 
24.  These findings, together with the low levels of pChk2 in untreated papillomas, shows that the 
levels of DNA damage in untreated tumors may be insufficient to trigger a DNA damage response.  
Thus tumor suppression by p53, at least in this model of epithelial cancer, is regulated by Arf and 
selection against p53 is driven by oncogenic signaling through Arf.   
Compared to epidermal cells, Atm has a more critical role in regulating p53 in lymphoid cells 17, so 
we also examined the interaction of Atm and p53 in spontaneous and IR induced lymphoma 
models.  The latency for spontaneous tumor development in Atm-/- mice (median age of 
death=116 days) was shorter than for p53-/- mice (median=141 days) (Figure 3A).  Tumor latency 
was significantly accelerated in Atm-/- p53-/- compound mutant mice (median=84 days) relative to 
either single mutant alone, consistent with a previous study 49.  ~95% of Atm-/- and Atm-/- p53-/- 
mice developed CD3 positive T cell lymphomas, which presented as enlarged thymi, with 
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occasional splenic or lymph node involvement.  The tumor spectrum differed slightly in the p53 
nulls.  60% developed thymic lymphoma and 40% developed other tumor types, mainly sarcomas 
(Table 2).  Thus, the reduced tumor latency in Atm-/- p53-/- mice was mainly due to acceleration of 
T cell thymic lymphomas.  
IR-induced p53 expression and apoptosis is markedly impaired in thymic lymphoid cells from adult 
Atm null mice 51, indicating Atm plays a central role in regulating p53 and apoptosis in these cells.  
We first verified that IR-induced apoptosis was impaired in thymocytes from young Atm deficient 
mice.  Results shown in Figure 3C show reduced apoptosis in irradiated Atm-/- thymus compared 
to wild type littermates.  If this Atm-dependent apoptotic pathway is critical for tumor suppression, a 
prediction is that germline Atm deficiency should effectively neutralize p53 in a radiation-induced 
tumor model.  An additional cohort of mice was treated at two days of age with a single dose of 1.4 
Gy.  Neonatal radiation reduced latency to tumor development in p53-/- mice from a median of 141 
days to 100 days (Figure 3B).  However, radiation did not noticeably affect tumor development in 
Atm-/- mice.  The median age to tumor development in irradiated Atm-/- mice was 113 days 
compared to 116 days in the non-irradiated cohort.  Tumor latency in irradiated Atm-/-p53-/- 
compound mutants (median = 72 days) was again reduced compared to either single mutant 
alone.  The predominant tumor type in all irradiated genotypes was CD3 positive T cell 
lymphomas, with a 95% incidence (Table 2).   
We next asked if loss of Atm reduced or eliminated selection against p53 during tumor 
development by examining loss of heterozygosity (LOH) of p53 in tumors from Atm-/- p53+/- mice.  
50% (4/8) of spontaneous thymic lymphomas and 89% (8/9) of IR-induced lymphomas from Atm-/-
p53+/- mice showed loss of the wild type p53 allele (Figure 4).  This is comparable to 57% (4/7) 
loss of p53 in lymphomas from p53+/- mice (Figure 4) and the range of 43-75% p53 LOH reported 
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in previous studies 19;22;27;37.  Thus, p53 loss occurs in tumors with or without the presence of Atm.  
Even under conditions where IR-induced p53-dependent apoptosis is disabled due to loss of Atm, 
selection against p53 remains.  This indicates that although Atm regulates p53 dependent 
apoptosis in response to acute DNA damage, other Atm independent pathways influence the 
tumor suppressor function of p53, even in a tumor model where DNA damage was the inducing 
agent.  This also implies that apoptosis is not the only mechanism of tumor suppression by p53.  
 
Discussion 
Here, we used three mouse models to compare the roles of Atm and p53 in suppression of 
oncogene and DNA damage induced tumor development.  We first compared the effect of deletion 
of Atm and p53 on progression of chemically induced skin tumors.  ~90% of DMBA/TPA induced 
papillomas have Hras mutations and these tumors showed increased staining for γ-H2AX, p53 and 
p21 compared to normal skin.  However staining for these markers was not significantly reduced in 
Atm null tumors indicating Atm is not required for activation of this tumor suppressor pathway in 
this autochthonous tumor model.  This is consistent with previous results showing that Atm is 
dispensable for acute IR induced p53 and apoptosis in epidermal hair follicle cells 17.  p53 can be 
activated by DNA damage in an Atm independent manner, for example through Atr, and these 
other pathways may compensate for the loss of Atm in regulating p53 in this tissue 33. 
Compared to wild type and Atm null tumors, Arf null tumors showed very little p53 expression and 
increased proliferation.  This indicates a central role for Arf in regulating p53 during tumor growth.  
That acute ionizing radiation was able to induce p53 in Arf null tumors 24, shows that exogenous 
DNA damage can induce p53 in tumors in the absence of Arf.  This further implies that the levels of 
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endogenous DNA damage or damage induced signaling which is present in untreated tumors may 
be insufficient to activate p53. 
The affects of Atm, Arf, and p53 on tumor progression were consistent with these signaling results.  
Deletion of both p53 and Arf but not Atm markedly accelerated the progression of benign 
papillomas to invasive malignant carcinomas.  In wild type mice, p53 loss is strongly selected for 
during progression of papillomas to carcinomas and p53 loss was less frequent in Arf null 
carcinomas. Together these results show that signaling through Arf induces p53 and this provides 
significant selective pressure against p53.      
We also found that the latencies for both spontaneous and radiation-induced lymphomas were 
accelerated in Atm p53 compound mutant mice relative to either single mutant alone.  This shows 
that loss of Atm and p53 can cooperate to accelerate tumor formation, and that p53 retains tumor 
suppressor activity in the absence of Atm.  Frequent loss of p53 in lymphomas from Atm-/- p53+/- 
mice indicates that selection against p53 does not require Atm, even in tumors induced by DNA 
damaging ionizing radiation.  This was surprising as IR-induced p53 expression and apoptosis is 
impaired in Atm null lymphocytes.  Our results are in general agreement with an elegant study by 
Christophorou et al., which showed that DNA damage-induced apoptosis is irrelevant for tumor 
suppression by p53 10.  In that study, selection against p53 was instead driven by oncogene-
mediated signaling through the p19/Arf tumor suppressor.  Liao and Van Dyke also concluded that 
there were two different mechanisms of tumor suppression by Atm and p53 30.   Lymphoma 
suppression in Atm null mice depended on V(D)J recombination, while lymphomas from p53 null 
mice arose independently of V(D)J recombination.  Atm has recently been implicated in repair of 
V(D)J breaks during antigen receptor rearrangement, and this function could play a role in 
lymphoma suppression by minimizing oncogenic translocations 6.  Consistent with this idea, 
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translocations involving the antigen receptors are frequently seen in lymphoid tumors from both AT 
patients 45 and Atm-/- mice 2;51.    
In summary, the requirement for Atm in regulating p53 in response to DNA damage varies between 
tissues and this may at least partially explain the tissue specific role of Atm in tumor suppression.  
In the tumor models we examined, loss of Atm did not phenocopy the loss of p53; that is, p53 
retained significant tumor suppressor activity in the absence of Atm.  This highlights that there are 
multiple and in some cases redundant signals that can activate p53 during tumor suppression.  In 
the case of Ras-driven skin tumors, Arf appears to play a more significant role than Atm in p53 
regulation and tumor progression.  Identifying the rate limiting steps in tumor progression in 
different tumor models and under different tumor etiologies remains an important goal in cancer 
research.  In the broader picture, understanding the nature of the selective pressures that drive 
tumor evolution is a necessary step to designing effective, mechanistically-based interventions.  
 
Materials and Methods: 
Mice.  F1 NIH/FVB;129 TRp53F2-10/+ mice 23 were crossed to N1 NIH/C57 K14-Cre mice47 and 
progeny intercrossed to generate experimental mice with the genotypes Trp53F2-10/F2-10 ( p53 WT) 
and Trp53F2-10/F2-10; K14-Cre (skin-specific p53 deficient).  PCR analysis confirmed that p53 was 
deleted in epidermis, but not liver, spleen, or thymus.  The backs of  8 week old p53 functional WT 
(n=22), and p53 functional null (n=29) mice were shaved and treated with a single application of 
DMBA (Sigma; 25 μg in 200 μl acetone) followed a week later by twice weekly applications of TPA 
(Sigma; 200 μl of 10-4 M solution in acetone) for 15 weeks. The number and size of papillomas on 
each mouse was recorded every week.  Mice were sacrificed if moribund or one to three weeks 
following detection of carcinomas.  All major organs were examined and tumors were frozen for 
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DNA extraction and/or fixed in formalin to be processed and stained with H&E for histological 
examination.  For the Atm skin tumor study, the Atm knockout allele was backcrossed 13 times to 
the susceptible NIH/Ola strain (Harlan Olac, UK).  Experimental mice of all three Atm genotypes 
were then generated from NIH/Ola Atm+/- breeders.  Atm-/- (n=18), Atm+/- (n=34), and Atm+/+ 
(n=25) mice were treated as above.  For the spontaneous and radiation induced tumor models, 
129/SvEv Atm+/- 3 and C57BL6 p53+/- mice 13 were intercrossed to generate experimental mice of 
the requisite combined Atm and p53 genotypes.  One cohort was left untreated and an additional 
cohort was irradiated at two days of age (1.4 Gy, using a 60Co irradiator).  Experimental mice were 
sacrificed and necropsied when exhibiting symptoms of tumor burden.   
Histological Analysis.  Sections of normal or tumor tissue were removed and either snap frozen or 
fixed for four hours in normal buffered formalin (NBF) and then processed to paraffin.   4 μm 
sections were cut, deparaffinized and stained for H&E, p53 (Novocastra CM5), p21 (BD 
Pharmingen), p16 (Abcam), cleaved caspase-3 (Asp175) (Cell Signaling Tech 9661), phospho-
histone H2A.X (Ser139) (Cell Signaling Tech 2577), or phospho-Chk2 (T68) (Abcam).  P19/Arf-/- 
papillomas stained for p53 were from a previous study 24.  Staining for all antibodies was done 
using a three step streptavidin technique. Sections were rehydrated and treated with high heat 
antigen retrieval using a 10mM citrate buffer (pH 6) and then stained with primary Ab.  After 
staining with the primary antibody the sections were stained with a biotin conjugated secondary 
(Vector labs) followed by StreptABComplex/HRP (DAKO).  Slides were developed with DAB/NiCl 
and counterstained with methyl green. Control sections with no primary antibody were run 
concurrently.  Other sections were cut and stained with H&E.   Apoptosis, proliferation and labeling 
indices were determined by counting the number of stained cells/400x field in five to seven 
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papillomas per Atm genotype.  All counts were done on a Nikon Labophot-2 microscope without 
knowledge of genotype.    
p53 loss of heterozygosity.  Genomic DNA was prepared from tumor tissue or normal kidney by 
QIAamp DNA Mini Kit (QIAGEN).  Wild type and knockout alleles of p53 from tumors from p53+/- 
mice were amplified in a separate reaction as described 46 for 30 cycles.  PCR products were 
electrophoresed on a 2% TAE agarose gel.  Comparison gradients for p53 were established by 
combining wild type and knockout genomic DNA in quantified ratios, then amplifying as described 
above. 
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Table 1. Conversion frequency of carcinomas to papillomas for mice that lived at least 20 weeks 
post DMBA. 
 
 
Table 2.  Tumor spectrum in Atm (AT) and p53 deficient mice. 
 
Spontaneous Irradiated
AT-/- p53-/- AT-/- p53+/- AT-/- p53+/+ AT+/+ p53-/- AT-/- p53-/- AT-/- p53+/- AT-/- p53+/+ AT+/+ p53-/-
Thymoma/Lymphoma 9 9 12 9 4 11 4 8
Sarcoma 1 0 0 2 0 0 0 1
Testicular Tumor 0 0 0 2 0 0 0 2
Brain Tumor 0 0 0 1 0 0 0 0
Multiple 2 1 0 2 0 0 0 0
Other 1 1 2 1 0 0 1 0
Total 13 11 14 17 4 11 5 11
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Figure legends 
 
Figure 1: Skin tumor development in Atm and p53 deficient mice.   A, DMBA/TPA induced 
papillomas in Atm deficient mice.  The mean number of papillomas per mouse of the indicated size 
class is plotted over time post DMBA treatment.  B, The average number of papillomas of all size 
classes from mice of the indicated Atm genotype is plotted over time post DMBA treatment.  C, 
Carcinoma free survival in DMBA/TPA treated mice.  (p=0.8 Atm-/- vs Atm+/+ and p=0.2 for Atm 
+/- vs Atm +/+, log rank test).  D, Tumor free survival in DMBA/TPA treated mice.  (p<0.0001 for 
Atm-/- vs. Atm+/+ and p= 0.11 for Atm+/- vs. Atm+/+, using log rank test).  E, DMBA/TPA induced 
papillomas in Trp53F2-10/F2-10 ( p53 WT) and Trp53F2-10/F2-10; K14-Cre (skin-specific p53 deficient) 
mice.  The number of papillomas in p53 deficient mice at 23 and 25 weeks was greater then wild 
types (p= 0.003 and 0.04 respectively, using an unpaired t-test).  F, Carcinoma free survival in 
DMBA/TPA treated p53 WT and skin specific p53 deleted mice (p53 conditional KO).  The 
difference was highly significant (p= 0.001 using the log rank test). 
Figure 2: DNA damage signaling in Atm deficient papillomas.  A, H&E stained sections and 
immunostaining for the indicated proteins from papillomas from wild type, Atm-/- and Arf-/- mice.  
Top row was photographed with a final magnification of 100x and lower rows at 600x.  B, 
Quantification of γ-H2AX, pChk2, p53, apoptosis, (APO) and mitotic index (MI), in Atm +/+, Atm-/- 
and Arf-/- papillomas (n=5-7 tumors per genotype).  The values were calculated as mean plus 
standard deviation of the number of cells that stained for γ-H2AX, pChk2, p53, or apoptotic or 
mitotic figures per 400x field. The p values were determined by the Mann-Whitney test. 
Figure 3: Loss of p53 and Atm cooperate during tumorigenesis. A, Spontaneous tumor 
development is accelerated in Atm-/-p53-/- (n=13) mice relative to Atm-/- (n=14) or p53-/- (n=18) 
mice.  B, IR-induced tumor development is accelerated in all genotypes except Atm-/- mice.  Atm-/-
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p53-/- mice (n=4) develop tumors faster then Atm-/- (n=8) or p53-/- (n=15) mice. C, IR induced 
apoptosis in thymus from 3 week old mice (4 Gy 4 h). The values are mean plus standard deviation 
of apoptotic figures per 400x field for 3-5 mice per genotype.  
Figure 4: p53 LOH is seen in tumors from both Atm+/+ and Atm-/- mice.  PCR analysis shows 
loss of the wild type allele of p53 in 4/7 spontaneous and 8/9 IR -induced tumors from Atm-/-p53+/- 
mice and from 4/7 tumors from p53+/- mice.  * indicates LOH of p53 in tumors. wt=wild type p53 
allele, mu= mutant p53 allele. 




